Creation of interferon-α8 mutants with amino acid substitutions against interferon-α receptor-2 binding sites using phage display system and evaluation of their biologic properties

Journal of Interferon and Cytokine Research

Volumn 29, Issue 3, 2009, Pages 161-169

  Yamamoto, Kouzo ^a   Taniai, Madoka ^a   Torigoe, Kakuji ^a   Yamamoto, Shigeto ^a   Arai, Norie ^a   Suemoto, Yasuo ^a   Yoshida, Kenshi ^a   Okura, Takanori ^a   Mori, Tetsuya ^a   Fujioka, Noboru ^a   Tanimoto, Tadao ^a   Miyata, Manabu ^a   Ariyasu, Harumi ^a   Ushio, Chie ^a   Fujii, Mitsukiyo ^a   Ariyasu, Toshio ^a   Ikeda, Masao ^a   Ohta, Tsunetaka ^a   Kurimoto, Masashi ^a   Fukuda, Shigeharu ^a  

^a HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON DERIVATIVE; ALPHA INTERFERON RECEPTOR; ALPHA2 INTERFERON; AMINO ACID; INTERFERON ALPHA 8; INTERFERON ALPHA RECEPTOR 2; INTERFERON ALPHA8 MUTANT 1; INTERFERON ALPHA8 MUTANT 2 010; INTERFERON ALPHA8 MUTANT 2 019; INTERFERON ALPHA8 MUTANT 2 064; INTERFERON ALPHA8 MUTANT 2 103; INTERFERON ALPHA8 MUTANT 2 106; INTERFERON ALPHA8 MUTANT 2 109; INTERFERON ALPHA8 MUTANT 2 111; INTERFERON ALPHA8 MUTANT 2 115; INTERFERON ALPHA8 MUTANT 29; INTERFERON ALPHA8 MUTANT 53; INTERFERON ALPHA8 MUTANT 8; INTERFERON CON1; MUTANT PROTEIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ANTIVIRUS AGENT; GROWTH INHIBITOR; IFNAR1 PROTEIN, HUMAN; IFNAR2 PROTEIN, HUMAN; INTERFERON ALPHA CON(1), METHIONYL; INTERFERON-ALPHA CON(1), METHIONYL-; PEPTIDE LIBRARY; RECOMBINANT INTERFERON;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; ASSOCIATION; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; CHEMICAL ENGINEERING; COMPARATIVE STUDY; CONTROLLED STUDY; DISSOCIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; KINETICS; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SEQUENCE ANALYSIS; BINDING COMPETITION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRAIN U937; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; SINDBIS VIRUS; SURFACE PLASMON RESONANCE; TUMOR CELL LINE; VESICULAR STOMATITIS VIRUS;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; GROWTH INHIBITORS; HEP G2 CELLS; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; KINETICS; MODELS, MOLECULAR; MUTATION; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, INTERFERON ALPHA-BETA; SINDBIS VIRUS; SURFACE PLASMON RESONANCE; U937 CELLS; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 61749086643     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0038     Document Type: Article

References (22)

1. Ariyasu T, Tanaka T, Fujioka N, Yanai Y, Yamamoto S, Yamauchi H, Ikegami H, Ikeda M, Kurimoto M. 2005. Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. In Vitro Cell Dev Biol Anim 41(1-2):50-56.
2. Benoit P, Maguire D, Plavec I, Kocher H, Tovey M, Meyer F. 1993. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J Immunol 150(3):707-716.
3. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Chuntharapai A, Gibbs V, Lu J, Ow A, Marsters S, Ashkenazi A, De Vos A, Jin Kim K. 1999. Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2. J Immunol 163(2):766-773.
5. Cleary CM, Donnelly RJ, Soh J, Mariano TM, Pestka S. 1994. Knockout and reconstitution of a functional human type I interferon receptor complex. J Biol Chem 269(29):18747-18749.
6. Guex N, Peitsch MC. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18(15):2714-2723.
7. Jacs E, Gavutis M, Uzé G, Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366(2):525-539.
8. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uzé G, Schreiber G. 2006. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 26(5):1888-1897.
9. Kalie E, Jaitin DA, Abramovich R, Schreiber G. 2007. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem 282(15):11602-11611.
10. Lorimer IAJ, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. 1996. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93(25):14815-14820.
11. Lu J, Chuntharapai A, Beck J, Bass S, Ow A, De Vos AM, Gibbs V, Jin Kim K. 1998. Structure-function study of the extracellular domain of the human IFN-alpha receptor (hIFNAR1) using blocking monoclonal antibodies: the role of domains 1 and 2. J Immunol 160(4):1782-1788.
12. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uzé G. 1999. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 19(10):1069-1098.
13. Novick D, Cohen B, Rubinstein M. 1994. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77(3):391-400.
14. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH. 1997. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 276(5317):1418-1420.
15. Piehler J, Roisman LC, Schreiber G. 2000. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem 275(51):40425-40433.
16. Platis D, Foster GR. 2003. Activity of hybrid type I interferons in cells lacking tyk2: a common region of IFN-α8 induces a response, but IFN-α2/8 hybrids can behave like IFN-β. J Interferon Cytokine Res 23(11):655-666.
17. Rani MR, Leaman DW, Han Y, Leung S, Croze E, Fish EN, Wolfman A, Ransohoff RM. (1999). Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 274(45):32507-32511.
18. Tanimoto T, Yamamoto S, Taniai M, Taniguchi M, Ariyasu H, Ushio C, Aga M, Mukai Y, Tsutsumi Y, Ariyasu T, Ohta T, Fukuda S. 2007. The combination of IFN-α2 and IFN-α8 exhibits synergistic antiproliferative activity on renal cell carcinoma (RCC) cell lines through increased binding affinity for IFNAR-2. J Interferon Cytokine Res 27(6):517-523.
19. Yamamoto S, Yano H, Sanou O, Ikegami H, Kurimoto M, Kojiro M. 2002. Different antiviral activities of IFN-α subtypes in human liver cell lines: synergism between IFN-α2 and IFN-α8. Hepatol Res 24(2):99-106.
20. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nagata S, Mayumi T. 2003. Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity. Nat Biotechnol 21(5):546-552.
21. Yanai Y, Horie S, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M, Kitamura T. 2001a. Characterization of the antitumor activities of IFN-α8 on renal cell carcinoma cells in vitro. J Interferon Cytokine Res 21(12):1129-1136.
22. Yanai Y, Sanou O, Kayano T, Ariyasu H, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M. 2001b. Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J Interferon Cytokine Res 21(10):835-841.